(111 days)
Yes
The device description explicitly states that a new option, "CleaRecon DL," based on Deep-Learning (DL) technology, is added. Deep Learning is a subset of Machine Learning.
No
Explanation: The device is described as a post-processing software application for 3D reconstruction of X-ray images, intended to assist physicians in diagnosis, surgical planning, interventional procedures, and treatment follow-up. It does not directly provide or administer therapeutic treatment.
Yes
The "Intended Use / Indications for Use" section states, "The 3D reconstructed Volume assist the physician in diagnosis, surgical planning, Interventional procedures and treatment follow-up." The explicit mention of assisting physicians in "diagnosis" indicates that this device is intended for diagnostic purposes.
Yes
The device description explicitly states that 3DXR is a "post-processing software-only application". While it relies on input from a hardware device (X-ray system) and runs on a hardware platform (AW), the device itself, as described, is solely the software performing the 3D reconstruction.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use clearly states that the device is for the three-dimensional reconstruction of images acquired from an X-ray interventional system for visualization. It assists physicians in diagnosis, surgical planning, interventional procedures, and treatment follow-up. This is focused on in vivo imaging and analysis of the human body.
- Device Description: The device is described as post-processing software for images acquired from a fixed interventional X-ray system. This further reinforces its role in processing images of the body, not samples taken from the body.
- Input Imaging Modality: The input is CBCT 3D acquisition images, which are images of the patient's body.
- Anatomical Site: The anatomical sites mentioned are vessels, bones, soft tissues, and other internal body structures. These are all parts of the living body.
In Vitro Diagnostics (IVDs) are defined as medical devices that are used to perform tests on samples taken from the human body, such as blood, urine, or tissue, to provide information for diagnosis, monitoring, or screening.
This device processes images of the body itself, not samples taken from the body. Therefore, it falls under the category of medical imaging software, not an In Vitro Diagnostic.
No
The provided text does not contain any explicit statements indicating that the FDA has reviewed, approved, or cleared a Predetermined Change Control Plan (PCCP) for this specific device. While PCCP is mentioned as a search term in the prompt, there is no relevant text within the input letter to support a "Yes" answer based on the decision rules.
Intended Use / Indications for Use
3DXR is the AW application which is intended to perform the three-dimensional (3D) reconstruction computation of any images acquired with a 3D Acquisition mode of the X-ray interventional system for visualization under Volume Viewer.
The 3D Acquisition modes are intended for imaging vessels, bones and soft tissues as well as other internal body structures.
The 3D reconstructed Volume assist the physician in diagnosis, surgical planning, Interventional procedures and treatment follow-up.
Product codes (comma separated list FDA assigned to the subject device)
OWB, QIH
Device Description
3DXR is a post-processing software-only application, runs on Advantage Workstation (AW) platform [K110834], and performs 3D reconstruction for the CBCT 3D acquisition images (input) acquired from the fixed interventional X-ray system [K181403, K232344]. The reconstructed 3D volume (output) is visualized under Volume Viewer application [K041521].
The proposed 3DXR is a modification from the predicate 3DXR [included and cleared in K181403]. A new option, called CleaRecon DL, based on Deep-Learning (DL) technology, is added in the proposed subject 3DXR application. This new CleaRecon DL option triggered this subject 510(k) submission.
The proposed 3DXR with CleaRecon DL option addresses the same user needs as predicate 3DXR. The goal of CleaRecon DL option is to remove streak artifacts caused by the pulsatile nature of blood flow around contrasted objects such as contrast medium injected vessels and stent structures.
The primary features/functions of the proposed software are:
- . 3D Reconstruction for the CBCT images.
- . CleaRecon DL: powered by a Deep-Learning algorithm, ability to remove streak artifacts caused by the pulsatile nature of blood flow and appearing around contrasted objects such as contrast medium injected vessels and devices.
- . 3DStent: ability to reconstruct coronary stent with the compensation of the respiratory and cardiac motion.
- Ability to read Imaging Purposes information on CBCT images (containing the acquisition system 3D preset information).
- Motion Freeze: ability to reduce the artifacts caused by involuntary respiratory motion.
- Metal Artifact Reduction (MAR): ability to reduce the artifacts induced by the presence of metallic devices.
- . Active Tracker Detection: allowing to localize and record Active Tracker position for future automatic registration of reconstructed volume with Ultrasound images.
- . Iodine Streaks Reduction: ability to reduce the streak artifacts induced by the high density of iodine.
- Scatter Reduction: ability to reduce the scatter-induced non-uniformities.
- Extended Range: allowing to increase the dynamic range of the 3D Volume.
- CT Format: labeling the reconstructed 3D Volume with CT format.
- Image Filters.
- 3D Volume Size selection.
- 3D Sub Volume selection.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Yes
Input Imaging Modality
X-ray (CBCT 3D acquisition images)
Anatomical Site
vessels, bones, soft tissues, other internal body structures. Specific examples mentioned in testing: Brain/Head, Liver/Abdomen, Prostate/Pelvic, Aorta/Stent-graft, Other anatomies.
Indicated Patient Age Range
No limitations on the patient population, except for CleaRecon DL option which is validated for adult population only.
Intended User / Care Setting
Physician / Interventional procedures
Description of the training set, sample size, data source, and annotation protocol
The CleaRecon DL algorithm was trained and qualified using pairs of images with and without streak artifacts.
Description of the test set, sample size, data source, and annotation protocol
Performance was first tested on a segregated test dataset of image pairs (with and without applying CleaRecon DL for streak artifact correction), independent from the dataset for training of CleaRecon DL algorithm.
A retrospective clinical image quality evaluation was conducted. 110 independent exams (each from a unique patient) coming from 13 clinical sites were used in this evaluation, including: Brain/Head: 20 patients, Liver/Abdomen: 30 patients, Prostate/Pelvic: 20 male patients, Aorta/Stent-graft: 20 patients, Other anatomies: 20 patients. These exams were retrospectively collected from the CBCT acquisitions performed with the fixed interventional X-ray system [K181403. K232344] on adult patients (pediatrics excluded) undergoing interventional procedures. 80 patients came from the US, 26 patients came from France, 4 patients came from Japan. These exams were anonymized. There were no inclusion criteria of age (within adult range) and sex/gender (except for prostate). These exams were independent and never used for the training and tuning of CleaRecon DL algorithm.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Engineering bench testing: Performance was first tested on a segregated test dataset of image pairs (with and without applying CleaRecon DL for streak artifact correction). Mean Absolute Error (MAE) and Structural Similarity Index Measure (SSIM) were computed for two samples. Acceptance criteria were reduction of MAE and increase of SSIM. A statistically significant reduction in MAE and increase in SSIM were observed between the two samples, concluding that CleaRecon DL option reduces streak artifacts on tested images. Performance was then tested on phantoms. CBCT images acquisitions made with the fixed interventional X-ray system [K181403, K232344] were performed with simulated streak artifacts conditions and without (reference). MAE with respect to the reference and standard deviation (SD) were computed to quantify streak artifact reduction. Acceptance criteria were reduction of MAE and SD. The reduction of both MAE and SD was observed, concluding that CleaRecon DL reduces streak artifacts on phantoms.
Clinical Testing: A retrospective clinical image quality evaluation was conducted using 110 independent exams. 13 clinicians were recruited. Each of the 110 exams (with and without applying CleaRecon DL) was presented side by side, with the same display conditions, and compared/evaluated at least 3 times independently, resulting in 490 pairs of clinicians' evaluations. The evaluation results met the predefined acceptance criteria and substantiated the performance claims. In 98% of the cases, the CBCT images reconstructed with CleaRecon DL option are evaluated as clearer than the conventional CBCT images. Within 489 reviews, clinicians did not identify any structure or pattern that has been hidden or artificially created by CleaRecon DL when compared to the original reconstruction.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Mean Absolute Error (MAE), Structural Similarity Index Measure (SSIM), Standard Deviation (SD) for engineering bench testing. For clinical testing: "98% of the cases, the CBCT images reconstructed with CleaRecon DL option are evaluated as clearer than the conventional CBCT images." and "Within 489 reviews, clinicians did not identify any structure or pattern that has been hidden or artificially created by CleaRecon DL when compared to the original reconstruction."
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1650 Image-intensified fluoroscopic x-ray system.
(a)
Identification. An image-intensified fluoroscopic x-ray system is a device intended to visualize anatomical structures by converting a pattern of x-radiation into a visible image through electronic amplification. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). An anthrogram tray or radiology dental tray intended for use with an image-intensified fluoroscopic x-ray system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9. In addition, when intended as an accessory to the device described in paragraph (a) of this section, the fluoroscopic compression device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Image /page/0/Picture/0 description: The image shows the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
February 25, 2025
GE Medical Systems SCS % Ning WEN Regulatory Affairs Program Manager 283 Rue De La Miniere BUC. 78530 FRANCE
Re: K243446
Trade/Device Name: 3DXR Regulation Number: 21 CFR 892.1650 Regulation Name: Image-Intensified Fluoroscopic X-Ray System Regulatory Class: Class II Product Code: OWB, QIH Dated: November 6, 2024 Received: January 24, 2025
Dear Ning WEN:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory
2
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Lu Jiang
Lu Jiang, Ph.D. Assistant Director Diagnostic X-Ray Systems Team DHT8B: Division of Radiological Imaging Devices and Electronic Products OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
| Submission Number (if known) | K243446 |
|---|---|
| Device Name | 3DXR |
| Indications for Use (Describe) | 3DXR is the AW application which is intended to perform the three-dimensional (3D) reconstruction computation of any images acquired with a 3D Acquisition mode of the X-ray interventional system for visualization under Volume Viewer. The 3D Acquisition modes are intended for imaging vessels, bones and soft tissues as well as other internal body structures. The 3D reconstructed Volume assist the physician in diagnosis, surgical planning, Interventional procedures and treatment follow-up. |
| Type of Use (Select one or both, as applicable) | Prescription Use (Part 21 CFR 801 Subpart D) |
| Over-The-Counter Use (21 CFR 801 Subpart C) | |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. |
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Image /page/4/Picture/1 description: The image shows the logo for GE HealthCare. The logo consists of the GE monogram in a circle on the left, followed by the text "GE HealthCare" on the right. The logo is purple in color and the text is in a sans-serif font.
K243446 510(k) Summary of Safety and Effectiveness
In accordance with 21 CFR 807.92 the following summary of information is provided.
| Date: | January 24, 2025 |
|---|---|
| Submitter: | GE Medical Systems SCS |
| Establishment Registration Number - 9611343 | |
| 283, rue de la Minière | |
| 78530 Buc, France | |
| Primary Contact: | Ning WEN |
| Regulatory Affairs Program Manager | |
| GE HealthCare, (GE Medical Systems SCS) | |
| Tel: +33 6 2324 6023 | |
| Email: ning.wen@gehealthcare.com | |
| Secondary Contact | Michelle Huettner |
| Regulatory Affairs Director | |
| Tel: +1 901 558 8035 | |
| Email: michelle.huettner@gehealthcare.com | |
| Device Trade Name: | 3DXR |
| Common/Usual Name: | 3DXR, with CleaRecon DL option |
| Regulation Number: | 21CFR 892.1650, Image-intensified fluoroscopic x-ray system |
| Primary Product Code: | OWB |
| Secondary Product Code: | QIH |
| Regulatory Class: | Class II |
| Predicate Device: | |
| Device Name: | 3DXR |
| Manufacturer: | GE Medical Systems SCS |
| 510(k) number: | K181403 |
| Regulation Number: | 21CFR 892.1650, Image-intensified fluoroscopic x-ray system |
| Product Code: | OWB |
| Regulatory Class: | Class II |
Device Description and Marketed Devices:
3DXR is a post-processing software-only application, runs on Advantage Workstation (AW) platform [K110834], and performs 3D reconstruction for the CBCT 3D acquisition images (input) acquired from the fixed interventional X-ray system [K181403, K232344]. The reconstructed 3D volume (output) is visualized under Volume Viewer application [K041521].
5
The proposed 3DXR is a modification from the predicate 3DXR [included and cleared in K181403]. A new option, called CleaRecon DL, based on Deep-Learning (DL) technology, is added in the proposed subject 3DXR application. This new CleaRecon DL option triggered this subject 510(k) submission.
The proposed 3DXR with CleaRecon DL option addresses the same user needs as predicate 3DXR. The goal of CleaRecon DL option is to remove streak artifacts caused by the pulsatile nature of blood flow around contrasted objects such as contrast medium injected vessels and stent structures.
The primary features/functions of the proposed software are:
- . 3D Reconstruction for the CBCT images.
- . CleaRecon DL: powered by a Deep-Learning algorithm, ability to remove streak artifacts caused by the pulsatile nature of blood flow and appearing around contrasted objects such as contrast medium injected vessels and devices.
- . 3DStent: ability to reconstruct coronary stent with the compensation of the respiratory and cardiac motion.
- Ability to read Imaging Purposes information on CBCT images (containing the acquisition system 3D preset information).
- Motion Freeze: ability to reduce the artifacts caused by involuntary respiratory motion.
- Metal Artifact Reduction (MAR): ability to reduce the artifacts induced by the presence of metallic devices.
- . Active Tracker Detection: allowing to localize and record Active Tracker position for future automatic registration of reconstructed volume with Ultrasound images.
- . lodine Streaks Reduction: ability to reduce the streak artifacts induced by the high density of iodine.
- Scatter Reduction: ability to reduce the scatter-induced non-uniformities.
- Extended Range: allowing to increase the dynamic range of the 3D Volume.
- CT Format: labeling the reconstructed 3D Volume with CT format.
- Image Filters.
- 3D Volume Size selection.
- 3D Sub Volume selection.
Intended Use:
3DXR is the AW application which is intended to perform the three-dimensional (3D) reconstruction computation of any images acquired with a 3D Acquisition mode of the X-ray interventional system for visualization under Volume Viewer.
Indications for Use:
3DXR is the AW application which is intended to perform the three-dimensional (3D) reconstruction computation of any images acquired with a 3D Acquisition mode of the X-ray interventional system for visualization under Volume Viewer.
The 3D Acquisition modes are intended for imaging vessels, bones and soft tissues as well as other internal body structures.
The 3D reconstructed Volume assist the physician in diagnosis, surgical planning, Interventional procedures and treatment follow-up.
6
Image /page/6/Picture/1 description: The image shows the logo for GE HealthCare. The logo consists of a purple circular emblem with a stylized "GE" monogram inside. To the right of the emblem, the words "GE HealthCare" are written in a simple, sans-serif font, also in purple. The logo is clean and modern, conveying a sense of trust and innovation.
Technology:
The proposed device 3DXR employs the same fundamental scientific technology as its predicate device 3DXR [K181403].
In addition, the proposed device 3DXR includes an option CleaRecon DL powered by a Deep-Learning (DL) Convolutional Neural Network (CNN) for removing streak artifacts. The CleaRecon DL algorithm was trained and qualified using pairs of images with and without streak artifacts.
Device Modification Overview:
The table below summarizes the substantive feature/technological differences and similarities between the predicate device and the proposed device:
| Specification | Predicate Device:
3DXR [K181403] | Proposed Device:
3DXR |
|--------------------------|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| Indications for Use | Identical | Identical |
| Patient Population | No limitations on the patient
population | Same, except for CleaRecon DL
option which is validated for adult
population only |
| 3D Reconstruction | Yes | Yes |
| CleaRecon DL | No, streak artifacts reduction by
Iodine Streaks Reduction only | Yes, streak artifacts removal
powered by DL-based algorithm |
| 3DStent | No, 3D reconstruction of moving
object with the compensation of
the respiratory motion | Yes, 3D reconstruction of coronary
stent with the compensation of the
respiratory and cardiac motion |
| Imaging Purposes | No, read multiple acquisition
system DICOM tags to identify
the clinical protocol | Yes, read acquisition system 3D
preset in Imaging Purposes DICOM
tag |
| Motion Freeze | Identical | Identical |
| Metal Artifact Reduction | Identical | Identical |
| Active Tracker Detection | Identical | Identical |
| lodine Streaks Reduction | Identical | Identical |
| Scatter Reduction | Yes | Yes |
| Extended Range | Identical | Identical |
| CT Format | Identical | Identical |
| Image Filters | Yes | Yes |
| 3D Volume Size selection | Identical | Identical |
| 3D Sub Volume selection | Yes | Yes |
7
Image /page/7/Picture/1 description: The image shows the GE Healthcare logo. The logo consists of a circular emblem on the left and the text "GE HealthCare" on the right. The emblem is a stylized, circular design with intertwined letters, and the text is in a simple, sans-serif font.
Determination of Substantial Equivalence:
Summary of Non-Clinical, Design Control Testing
The proposed device, 3DXR, has successfully completed the required design control testing per GE HealthCare Quality Management System. No additional hazards were identified, and no unexpected test results were observed. The proposed device complies with NEMA PS 3.1 - 3.20 Digital Imaging and Communications in Medicine (DICOM) Set (Radiology) standard. It was designed and manufactured under the Quality System Regulations of 21CFR 820 and ISO 13485.
The following quality assurance measures were applied to the development of the device:
- . Requirements Definition
- . Risk Analysis
- . Technical Design Reviews
- . Formal Design Reviews
- Software Development Lifecycle
- . Performance testing (Verification, Validation)
- . System Testing (Verification, Validation)
The proposed 3DXR has been successfully verified on the AW VolumeShare workstation [K110834] platform. All of the testing and results did not raise new or different questions of safety and effectiveness other than those already associated with the predicate device.
The substantial equivalence determination is also based on the software documentation for a BASIC level.
Additional Non-Clinical Testing
Engineering bench testing was used to demonstrate the performances of the new CleaRecon DL algorithm's capabilities to remove streak artifacts from CBCT reconstructions.
Performance was first tested on a segregated test dataset of image pairs (with and without applying CleaRecon DL for streak artifact correction), independent from the dataset for training of CleaRecon DL algorithm. Mean Absolute Error (MAE) and Structural Similarity Index Measure (SSIM) were computed for two samples. Acceptance criteria were reduction of MAE and increase of SSIM. A statistically significant reduction in MAE and increase in SSIM were observed between the two samples. It was thus concluded that the CleaRecon DL option reduces streak artifacts on tested images.
Performance was then tested on phantoms. CBCT images acquisitions made with the fixed interventional X-ray system [K181403, K232344] were performed with simulated streak artifacts conditions and without (reference). MAE with respect to the reference and standard deviation (SD) were computed to quantify streak artifact reduction. Acceptance criteria were reduction of MAE and SD. The reduction of both MAE and SD was observed leading to the conclusion that CleaRecon DL reduces streak artifacts on phantoms.
8
Image /page/8/Picture/1 description: The image shows the GE HealthCare logo. The logo consists of a purple circular emblem with a stylized "GE" monogram inside. To the right of the emblem, the words "GE HealthCare" are written in a simple, sans-serif font, also in purple.
The engineering bench testing passed the predefined acceptance criteria, demonstrated the CleaRecon DL performance to remove streak artifacts, and no degradation of image quality, nor other concerns related to safety and performance were observed.
Summary of Clinical Testing
A retrospective clinical image quality evaluation was conducted to demonstrate the performances of the new CleaRecon DL algorithm's capabilities to remove streak artifacts from CBCT reconstructions and to ensure final validation of CleaRecon DL derived outputs.
110 independent exams (each from a unique patient) coming from 13 clinical sites were used in this evaluation, including:
Brain/Head: 20 patients Liver/Abdomen: 30 patients Prostate/Pelvic: 20 male patients Aorta/Stent-graft: 20 patients Other anatomies: 20 patients
These exams were retrospectively collected from the CBCT acquisitions performed with the fixed interventional X-ray system [K181403. K232344] on adult patients (pediatrics excluded) undergoing interventional procedures. 80 patients came from the US, 26 patients came from France, 4 patients came from Japan. These exams were anonymized. There were no inclusion criteria of age (within adult range) and sex/gender (except for prostate). These exams were independent and never used for the training and tuning of CleaRecon DL algorithm.
13 clinicians were recruited for this evaluation. Each of the 110 exams (with and without applying CleaRecon DL) was prepared so that the conventional reconstruction images and the images reconstructed with CleaRecon DL option were presented side by side on AW, with the same display conditions, and were compared / evaluated at least 3 times independently, resulting in 490 pairs of clinicians' evaluations.
For each image comparison, the physicians were asked (through 8 questions):
- to evaluate the impact of CleaRecon DL on CBCT image quality, -
- । to confirm that CleaRecon DL removes streaks artifacts and assess whether it brings other artifacts when compared to the conventional CBCT reconstruction.
- to assess if CleaRecon DL provides a clearer image and how it impacts their confidence in image interpretation.
- to assess if it brings artificial structures and/or hides important anatomical structures.
The evaluation results met the predefined acceptance criteria and substantiated the performance claims. In 98% of the cases, the CBCT images reconstructed with CleaRecon DL option are evaluated as clearer than the conventional CBCT images.
Within 489 reviews, clinicians did not identify any structure or pattern that has been hidden or artificially created by CleaRecon DL when compared to the original reconstruction.
9
Image /page/9/Picture/1 description: The image contains the GE Healthcare logo. The logo consists of a purple circular emblem with a stylized "GE" monogram inside. To the right of the emblem, the words "GE HealthCare" are written in a simple, sans-serif font, also in purple. The overall design is clean and corporate, representing the brand identity of GE Healthcare.
Substantial Equivalence Conclusion
The changes to the predicate device 3DXR do not create new Intended Use nor Indication for Use. The proposed device 3DXR has identical or substantially equivalent technological characteristics as its predicate device.
GE HealthCare's quality system's design, verification, and risk management processes did not identify any new questions of safety or effectiveness, hazards, unexpected results, or adverse effects stemming from the changes to the predicate.
Based on the development under GE HealthCare's quality system, successful design verification and validation, software documentation for a "Basic" level, along with the engineering bench testing and the clinical evaluation by physicians demonstrate that the proposed 3DXR is substantially equivalent to, and hence as safe and as effective for its Intended Use as the legally marketed predicate device.